Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Aptevo Therapeutics Inc. - Common Stock
(NQ:
APVO
)
1.350
-0.040 (-2.88%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aptevo Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
Next >
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors
November 10, 2025
Via
ACCESS Newswire
Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update
November 06, 2025
Via
ACCESS Newswire
Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter
October 08, 2025
Via
ACCESS Newswire
TOMI Environmental Solutions (NASDAQ: TOMZ): The Next Era of Disinfection Technology – More Stocks Inside
September 16, 2025
Via
AB Newswire
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
February 15, 2025
Via
ACCESS Newswire
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update
February 14, 2025
Via
ACCESS Newswire
Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML
September 16, 2025
Via
ACCESS Newswire
Foremost Clean Energy and Aptevo Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
September 05, 2025
Via
ACCESS Newswire
Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules
September 04, 2025
Via
ACCESS Newswire
Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
August 13, 2025
Via
ACCESS Newswire
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update
August 11, 2025
Via
ACCESS Newswire
Aptevo Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
August 08, 2025
Via
ACCESS Newswire
Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules
June 20, 2025
Via
ACCESS Newswire
Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers
June 20, 2025
Via
ACCESS Newswire
Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules
June 18, 2025
Via
ACCESS Newswire
Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML
June 18, 2025
Via
ACCESS Newswire
Aptevo Participating in the BIO International Convention
June 13, 2025
Via
ACCESS Newswire
Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan
May 22, 2025
Via
ACCESS Newswire
Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig
May 14, 2025
Via
ACCESS Newswire
Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation
May 08, 2025
Via
ACCESS Newswire
Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
April 22, 2025
Via
ACCESS Newswire
Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
April 21, 2025
Via
ACCESS Newswire
Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
April 04, 2025
Via
ACCESS Newswire
$2 Stocks to Watch: PNPN.V, TIVC, APVO, OSRH, PRSO Biotech Breakthroughs, MedTech Momentum Metallic Metals Power Play & Signal Innovation
April 03, 2025
Via
AB Newswire
Topics
Intellectual Property
Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
April 03, 2025
Via
ACCESS Newswire
RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment
March 20, 2025
Via
ACCESS Newswire
Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy
March 18, 2025
Via
ACCESS Newswire
Aptevo to Participate in March Conferences
March 06, 2025
Via
ACCESS Newswire
Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025
January 15, 2025
Via
ACCESSWIRE
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds
December 12, 2024
Via
ACCESSWIRE
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
